aConclusion: The novel oral P2Y12 inhibitorsprasugrel and ticagrelor have typical benefits over the use of clopidogrel for patients with CAD. Findings of this study provided some useful evidence for proper selection of these drugs in clinical practice. Conclusión: El inhibitorsprasugrel P2Y12 y el ...
One reason for limited success of antiplatelet drugs is high on-treatment platelet reactivity during sepsis. In fact, recent data suggests that sepsis promotes platelet activation despite treatment with P2Y12 inhibitors, which are common antiplatelet drugs used in the secondary prevention of arterial thr...
• Are receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that can- not be discontinued or are anticipated to require > 2 weeks of daily treatment with NSAID or COX2 inhibitors during the study. • Concomitant therapy with a ...